Bethlehem, PA – March 1, 2012. The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) announced today an investment of $250,000 in Micro Interventional Devices, Inc. (MID), a developer of structural heart repair technologies.
MID’s initial product offering is a minimally invasive device known as Permaseal™, which provides access and wound closure during structural heart repair procedures. Designed to move with the beating heart while still keeping the edges of the wound closed, the Permaseal device not only enables wound healing without the use of sutures, it is cost- and time-efficient.
“The Permaseal access and closure device will enable unprecedented safe and reliable transmyocardial access for structural heart repair procedures,” says Michael Whitman, President & CEO. “It is our hope that Permaseal becomes the new standard of care for access and closure for these procedures.”
The patent pending Permaseal technology allows the surgeon to remotely affix a biocompatible implant to the apex of the heart, creating an “access site” on the myocardial surface of the heart. This provides sutureless access for a wide range of structural heart repair procedures including transcatheter aortic valve implantation (TAVI), transcatheter mitral valve replacement, mitral valve repair and other emerging structural heart repair procedures.